DMK PHARMACEUTICALS Corp: going-concern / distress — DMK Pharmaceuticals files Chapter 11; expects Nasdaq delisting, stock may become worthless

DMK PHARMACEUTICALS Corp

Filed voluntary Chapter 11 petitions on Feb 2, 2024 in Delaware Bankruptcy Court.
Will operate as debtor-in-possession; seeks court approval to continue paying wages, salaries, benefits.
Expects Nasdaq delisting notice; will not appeal, so common stock will be delisted.
Caution: trading in securities highly speculative; stockholders could experience significant or complete loss.

Key facts

Extracted from this filing and checked against the source text.

Distress & Bankruptcy SEC 8-K Item 1.03 confidence 0.9

DMK PHARMACEUTICALS Corp entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2024-02-02).

Proceeding: chapter 11
Court: United States Bankruptcy Court for the District of Delaware
Petition: 2024-02-02

Exact text from the filing

On February 2, 2024 (the “Petition Date”), DMK Pharmaceuticals Corporation (the “Company”) and certain of its direct and indirect subsidiaries (collectively, the “Company Parties”) commenced bankruptcy cases (the “Chapter 11 Cases”) by filing voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”).

View on SEC.gov

Browse all distress & bankruptcy →

Source: SEC EDGAR

accession 0001839882-24-003361

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.